Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | CPA1 | P15085 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907446 | 1.00 | CTNNB1 (0.59) | CTNNB1KDM4EAPAF1POLBMAPT | |
| SCHEMBL25846959 | 1.00 | CTNNB1 (0.59) | CTNNB1KDM4EAPAF1POLBMAPT | |
| SCHEMBL3146178 | 0.87 | KDM4E (0.51) | CTNNB1KDM4EAPAF1POLBMAPT | |
| SCHEMBL10421147 | 0.87 | CTNNB1 (0.54) | CTNNB1KDM4EAPAF1POLBMAPT | |
| SCHEMBL16743938 | 0.86 | CTNNB1 (0.55) | CTNNB1KDM4EL3MBTL1TDP1MMP9 | |
| SCHEMBL6623784 | 0.86 | CTNNB1 (0.55) | CTNNB1KDM4EL3MBTL1TDP1MMP9 | |
| SCHEMBL13879137 | 0.86 | CTNNB1 (0.55) | CTNNB1KDM4EL3MBTL1TDP1MMP9 | |
| SCHEMBL8874713 | 0.85 | CTNNB1 (0.54) | CTNNB1KDM4EL3MBTL1TDP1MMP9 | |
| SCHEMBL1284854 | 0.85 | CTNNB1 (0.54) | CTNNB1L3MBTL1TDP1MMP9MMP8 | |
| SCHEMBL7272663 | 0.84 | CTNNB1 (0.75) | CTNNB1MAPTTDP1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | RA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022148843-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| US-20140256912-A1 | Stabilized Variant MAML Peptides and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | VIP, HAVCR2, NGLY1 | CTNNB1 2641/4885KDM4E 3724/4885APAF1 775/4885 |
| US-20140256912-A1 | Stabilized Variant MAML Peptides and Uses Thereof | NOTCH1, MDN1, NOTCH2 | CTNNB1 1697/4885KDM4E 3647/4885APAF1 1137/4885 |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | CTNNB1 1375/4885KDM4E 4154/4885APAF1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.